NCT06164262 Dementia Risk Registry for Young and Middle-aged CSVD Patients in the Next 10 Years
| NCT ID | NCT06164262 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Provincial People's Hospital |
| Condition | Cerebral Small Vessel Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2034-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-01-01 with a primary completion date of 2034-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Age-related cerebral small-vessel disease (CSVD) is a major cause of dementia, predominantly affecting individuals over 60 years of age, with a prevalence exceeding 70% in the elderly population. However, the correlation between the burden of CSVD and the progression of cognitive impairment in young and middle-aged individuals remains uncertain. DREAM-10 is an observational, prospective study that enrolled individuals aged 30-60 years, who were free from known dementia but exhibited imaging markers related to CSVD. Through prospective registration and follow-up, this study will collect data on patients with CSVD, including clinical information, neuropsychological assessments, multimodal Magnetic Resonance Images (MRI) and retinopathy characterized by Optical Coherence Tomography Angiography (OCTA). CSVD related features seen on neuroimaging include recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, brain atrophy, cortical superficial siderosis. Utilizing this data, the researchers aim to investigate the potential dementia risk among young and middle-aged individuals with CSVD over the forthcoming decade, along with identifying its predictive factors.
Eligibility Criteria
Inclusion Criteria: 1. Patients with any of the CSVD-related MRI imaging markers, including recent small subcortical infarcts, lacunes, white matter hyperintensities, perivascular spaces, microbleeds, and superficial cortical siderosis. 2. Patients aged from 30 to 60 years. 3. Sign informed consent. Exclusion Criteria: 1. Unable to cooperate with inspectors. 2. Known dementia. 3. Other cognitive diseases (such as Alzheimer's disease, Parkinson's disease, or thyroid disease). 4. Serious systemic illness, such as heart, liver, kidney disease or major mental illness. 5. Contraindications for imaging examination. Exit Criteria: 1. Not meet the inclusion criteria. 2. For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator. 3. Any adverse or serious adverse events during the study period judged by investigator.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06164262 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 60 Years, studying Cerebral Small Vessel Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06164262 currently recruiting?
Yes, NCT06164262 is actively recruiting participants. Contact the research team at zhangsheng@hmc.edu.cn for enrollment information.
Where is the NCT06164262 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06164262 clinical trial?
NCT06164262 is sponsored by Zhejiang Provincial People's Hospital. The trial plans to enroll 1,000 participants.